In the last decade, transcatheter aortic valve implantation (TAVI), a disruptive technology, has revolutionized the therapy of symptomatic severe aortic stenosis, and current guidelines state that the recommendations for TAVI and surgical aortic valve replacement (SAVR) are equivalent in patients at high-risk. Increased operator experience, technical advances in the new generation of transcatheter heart valves (THV) and excellent TAVI results in recently published randomized controlled trials have led to the expansion of TAVI indication as an alternative to SAVR in intermediate-risk subjects, given appropriate patient selection. The time is opportune to examine the role of TAVI in low-risk patients, currently the objective of on-going randomized trials. This review aims to summarize the available knowledge on TAVI in low-to intermediate-risk patients and to discuss the potential advantages and pitfalls TAVI will face in this clinical setting.
Introduction
Transcatheter aortic valve implantation (TAVI) has rapidly become the treatment of choice in patients with severe symptomatic aortic stenosis (AS) considered inoperable, and in patients at high surgical risk the recommendations for TAVI are equivalent to SAVR. 1, 2 The technical advances in new generations of transcatheter heart valves (THV) have led to an impressive improvement in TAVI safety and efficacy. The excellent TAVI results observed in recently published randomized controlled trials 3 and multiple international prospective registries [4] [5] [6] [7] have broadened the indications for TAVI to intermediate-risk patients as an alternative (class IIa, LoE B) to SAVR. 8 With this background in mind, there are good reasons to believe that TAVI might become a valuable treatment option for a large number of lower (intermediate-to low-) risk patients, which represent over 80% of subjects currently undergoing SAVR. 9 Notwithstanding, several aspects need a more in depth analysis. This review aims to summarize the evidence supporting the expansion of TAVI to lower-risk patients, to analyse the caveats of risk score assessment and to discuss the potential advantages and pitfalls that TAVI will face in this category of patients.
Definition of risk
How do we define the risk of a TAVI procedure? Risk models are useful decision-making tools designed to estimate procedural outcomes and intended for patient counselling, clinical research, and-in many health care systems-financial reimbursement. 10 Both in clinical practice and in randomized trials, the risk scores used to judge a patient's indication for TAVI have been inherited from surgical procedures. The Society of Thoracic Surgeons predicted risk for mortality (STS) 11 and the logistic European System for Cardiac
Operative Risk Evaluation (EuroSCORE I and II) 12, 13 are the most widely used scores in North America and Europe, respectively. Detailed description of variables included in the different risk scores is reported in Table 1 . Although risk categories are not dichotomous variables but rather to be considered as a continuum, patients nonetheless are generally considered at high-risk with an STS score >8% or a logistic EuroSCORE >20%, at intermediate-risk when STS score is 4-8% and logistic EuroSCORE is 10-20%, at low-risk with an STS score of <4% and logistic EuroSCORE <10%. However, while surgical risk models correctly predict SAVR outcomes (showing accurate discrimination and calibration), 14, 15 they significantly overestimate TAVI mortality (Take home figure). difference between predicted and observed mortality) of surgical scores in TAVI is related to many confounders, including the fact that with TAVI general anaesthesia is often not needed, and as a consequence most variables present in the surgical scores (such as chronic pulmonary disease and renal insufficiency, etc.) have a lesser influence on TAVI outcomes. Of note, several new TAVI risk models [16] [17] [18] [19] [20] [21] have been developed, but none is routinely used nor is included in on-going trials, mostly because of their complexity, poor accuracy (low c statistic) and entry bias in regard to patient inclusion (i.e. older age, surgical refusal, etc.) that preclude broad generalization. 20 Accordingly, the guidelines acknowledge the imperfect nature of surgical risk scores, and recommend that the decision to perform TAVI should be made on the basis of multidisciplinary Heart Team evaluation. 8 In other words, risk scores should never be a substitute for thoughtful clinical judgment and the participation of patients and their families in the decision. It is well documented that age remains one the most important reasons for surgical refusal, 22 and referral to TAVI. In this regard, in the STS registry, SAVR patients had a mean age of 67 years and a mean STS of 1.8% (only 6.2% patients had an STS >8%), and there was a clear correlation between STS value and age. On the other hand, the common thread across TAVI trials and registries remains the older age, regardless of risk score (Take home figure) . Indeed, despite the absence of an absolute age cut-off in the inclusion criteria for most studies, TAVI patients in all major recent and on-going trials are still prodominantly octogenarians. This implies that 'lower-risk' does not necessarily mean 'younger'. The relative lack of major comorbidities illustrates the common entity of entry bias in previous and on-going trials comparing SAVR with TAVI, in which patients had to be considered eligible for both procedures in order to be included (for instance, in the PARTNER trial, less than one-third of the screened patients were eventually enrolled 23 ) A similar situation has been noted in trials of coronary revascularization procedures. 24 This is illustrated by the demographics of patients in clinical practice at large, in which the indication for TAVI is not simply based on surgical scores, as shown by the fact that almost 2/3 of patients included in contemporary European registries are at intermediate and even low surgical risk. Accordingly, in the STS/ACC Transcatheter Valve Therapy Registry TAVI patients have a mean STS score of 6.7%, and almost 70% of them are > _80 years of age. 25 Evidence from randomized trials and registries in lower-risk patients
Details of study characteristics and results of head-to-head comparisons between SAVR and TAVI in intermediate-low risk patients are reported in Tables 2 and 3 .
PARTNER 2
The age 81.5 years, mean STS score 5.8%), who were randomized either to TAVI with the balloon-expandable SAPIEN XT system (Edwards Lifesciences) or to SAVR. In this study, TAVI was non-inferior to SAVR with respect to all-cause death or disabling stroke at 2 years [19.3% in the TAVI group vs. 21 .1% in the SAVR group; HR in the TAVI group 0.89; 95% confidence interval (CI), 0.73 to 1.09; P = 0.25]. Transcatheter aortic valve implantation resulted in lower rates of acute kidney injury, severe bleeding and new-onset atrial fibrillation, but was associated with higher rates of major vascular complications and significant paravalvular leak (PVL). Importantly, when considering only patients treated with transfemoral approach, the TAVI group had a lower incidence of death or disabling stroke compared with SAVR (HR 0.79; 95% CI, 0.62 to 1.00; P = 0.05).
SURTAVI
In the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) trial, 26 35 Interestingly, in this analysis, throughout the year 2014, more patients with severe AS received a transfemoral TAVI than SAVR, mean age of TAVI patients was 78 years and about one third of them were at low surgical risk, as defined by EuroSCORE. The overall impact of TAVI vs. SAVR on the combined endpoint of death and stroke rate at 1-year in lower-risk patients included in published studies is shown in Figure 1 . TAVI trends to be superior to SAVR with a relative risk reduction of 13% of mortality and stroke at 1-year, without significant heterogeneity across studies.
On-going trials in low-risk patients
On-going randomized trials on low-risk TAVI patients are shown in Table 4 . Notably, this studies do not have prespecified age cut-offs and, in contrast to previous trials in patients at intermediate risk, will focus mainly on transfemoral TAVI which with the new generation prostheses is feasible in more than 85% of TAVI procedures. 36 This implies that TAVI patients enrolled in these trials will mostly be treated with the "minimalist approach", not requiring general anaesthesia and therefore potentially leading to less complications, accelerated recovery, shorter length of hospital stay (up to 40%), reduced costs 37 and better quality of life. 
Potential advantages and pitfalls of TAVI in lower-risk patients Stroke
Disabling stroke, although rare, is associated with a 3-fold increase in mortality after both SAVR and TAVI, 39, 40 and represents a devastating complication, especially when occurring in younger patients. Despite the initial concern about a potential increase in stroke rate in the first 30 days associated with TAVI in PARTNER 1, no difference between TAVI and SAVR was seen in the same cohort after longerterm follow-up. 23, 41, 42 Continuous improvement in TAVI technology, such as a reduction in the profile of delivery catheters which traverse the arch and cross the aortic valve has improved the ease of prosthesis positioning with less need for manipulation within the annulus and lower rates of pre-and post-dilatation. This has led to a dramatic reduction in 30-day disabling stroke rates with TAVI, which is now as low as 1.0-1.2% in intermediate-risk patients treated with newergeneration devices. 9, 26 Of note, in both major intermediate-risk trials the rate of disabling stroke was numerically although not statistically significantly lower in the TAVI arm compared with SAVR. 3, 26 Since every effort should be made to minimize cerebral embolic events, especially in low-risk patients, there is debate as to whether younger subjects might benefit from routine use of neuroembolic protection devices. In this regard, two randomized trials of embolic protection devices found no advantage in terms of disabling stroke reduction (perhaps because of the low event rate overall) although there was a significantly lower frequency of clinically silent ischaemic cerebral lesions as detected by magnetic resonance imaging. 43 Nevertheless, given its good safety profile and potential clinical benefit (despite the neutral results of randomized trials), the US Food and Drug Administration has recently cleared one of these cerebral protection systems (Sentinel, Claret Medical). Importantly, the impact of the apparently silent ischaemic lesions on long-term neurological and cognitive function is largely unknown and this issue may be particularly relevant if TAVI is offered to lower-risk and younger patients. Besides peri-procedural strokes, mid-and long-term thrombo-embolism is increased by new-onset atrial fibrillation, which has consistently been more frequently observed with SAVR than TAVI, independently of age and surgical risk. 3, 26 Currently, adjunctive pharmacotherapy after TAVI is not standardized, especially in patients who require the combination of oral anticoagulation and anticoagulation. Several on-going trails will address this issue ( Table 5) . Subclinical leaflet thrombosis (detected at cardiac computed tomography) is a finding more often associated with transcatheter than surgical bioprostheses. [44] [45] [46] [47] Nevertheless, data from randomized trials across all risk categories did not show any differences in the risk of stroke or valve durability at 5 years. Although rates of disabling strokes do not appear to be different in patients with reduced leaflet motion, transient ischaemic attacks are more common. Interestingly, anticoagulation with novel oral anticoagulants or warfarin, but not dual antiplatelet therapy, is effective in prevention and resolution of leaflet thrombosis and subsequent impaired leaflet motion. To note, the PARTNER 3 trial will have a dedicated imaging sub-study, with 200 patients undergoing routine computed tomography follow-up.
Paravalvular regurgitation
Paravalvular leakage (PVL) after SAVR is a rare occurrence, involving less than 1% of patients. 48 Despite improvements in procedural planning (with multi-detector computed tomography evaluation for accurate valve sizing) and technological advances in valve design (such as the development of fully repositionable and retrievable THVs, and the addition of an outer skirt to fill the annulus-prosthesis interface), it is likely that TAVI will remain inferior to surgery with regard to incidence of PVL even as we move into lower-risk patients. Factors that are independent of age and surgical risk, such as the presence of bulky calcifications (both in the annulus and left ventricular outflow tract), eccentric annulus and bicuspid anatomy, will continue to affect TAVI performance on PVL. Nevertheless, the incidence of moderate/severe PVL has dramatically dropped with new-generation THVs, and in the two major intermediate-risk trials more than 2/3 of PVL after TAVI were considered mild, with a difference between self-expandable and balloonexpandable THVs (Figure 2) . There is evidence in the literature that acute mild PVL, especially after self-expandable device implantation, can improve over time (at mid-term follow-up), presumably because of positive remodelling between the prosthesis-annulus interface. While data on the influence of mild PVL on outcome in high-risk patients are controversial, its impact in lower-risk patients is completely unsettled. In particular, unknown is the potential impact of mild PVL on THV long-term durability, and if PVL could possibly worsen at long-term follow-up, particularly in patients with extensive and progressive calcifications.
Pacemaker implantation
Conduction disturbances are more frequent after TAVI than SAVR, 49 and often require permanent PM implantation. In general, self-expandable devices carry a higher risk of PM implantation when compared with balloon-expandable THVs. 3, 26, 50 Unlike most other TAVI complications, the incidence of PM implantation has seen a slight increase with the introduction of new-generation THVs, and this has been linked to the additional external fabric cuff to minimize PVL. 51 New PM implantation rates were no different between high and intermediate-risk patients and this is likely because conduction disturbances, just as PVL, are mostly influenced by valve design and anatomical features, which are independent from age and surgical risk. However, evidence regarding long-term impact of PM implantation have been equivocal, [52] [53] [54] in part because atrioventricular node disturbances can resolve days to weeks after TAVI, 55, 56 reducing the percentage of right ventricular pacing and consequent loss of ventricular synchrony. Moreover, in higher-risk patients the negative effect of chronic ventricular pacing could be masked by the severity of comorbidities. 57, 58 As for mild PVL, it is unknown how frequently PM implantation and ventricular asynchrony will adversely affect mortality or physical performance over longer-term follow-up in more active, younger patients, as suggested by recently published data after SAVR. 59 Furthermore, PM implantation in young patients may expose the recipient to the risk of PM-related complications, such as lead infection, endocarditis and for lead-induced tricuspid insufficiency, for a longer period of time.
Bicuspid aortic stenosis
As we begin to perform TAVI in younger patients, the prevalence of bicuspid AS will considerably increase ( Figure 3) . Surgical series of isolated SAVR suggest that in a population with a mean age of 70 years Adapted from Roberts et al. 60 . bicuspid AS is at least as frequent as the classic degenerative senile tricuspid AS, and even higher among 50-year-olds. 60 Notably, current TAVI evidence is based on tricuspid AS, since patients with congenital bicuspid AS were excluded from all major randomized trials.
3,27,61,62 Therefore, we do not have definitive data on how THVs perform against surgery in the presence of bicuspid valves, although such studies are ongoing. Nevertheless, current guidelines do not list bicuspid AS as a contraindication to TAVI. 8 Percutaneous treatment of bicuspid stenosis has been always associated with increased procedural risk (more frequent occurrence of aortic root injury) and suboptimal short-term result (higher rates of PVL), although a recent propensity-score matching study of TAVI in bicuspid vs. tricuspid valves demonstrated a similar prognosis. 63 Moreover, patients with bicuspid aortic valves treated with newgeneration devices had lower rate of aortic root injury and moderate/severe PVL than patients receiving a first-generation THV, with results similar to TAVI in tricuspid AS. In fact, the increased procedural challenges in treating tricuspid AS (such as annular eccentricity and asymmetric valve calcification) have been mitigated by the incorporation of the outer skirt and the repositioning capacity of newgeneration THVs, which reduce PVL rate and the risk for aortic root injury associated with extreme prosthesis oversizing. Nevertheless, several other important factors should be taken into account when considering a younger patient with bicuspid AS for TAVI. For instance, younger patients often have concomitant aortic root disease (i.e. aortic root aneurysm) with higher risk of aortic rupture and dissection, 64 and frequently present with a lower coronary take-off, which could increase the risk for coronary occlusion during the procedure or make coronary cannulation more challenging in the future. All these considerations mandate careful pre-procedural imaging (i.e. computed tomography) evaluation in order to prevent potential pitfalls during valve deployment.
Small aortic annulus
On the other hand, a subset of low-risk and younger patients that are expected to perform better with TAVI than SAVR are those with a small aortic annulus. It is well established that subjects with severe patient-prosthesis mismatch after SAVR have impaired prognosis and reduced survival. 65 This is particularly true for young patients, in which a significant residual gradient impacts negatively on every-day life activities. Compared with SAVR, TAVI has consistently shown more favourable haemodynamics (greater increase in valve area and reduced transprosthetic gradients), probably due to the ability of THVs to expand to the anatomical annulus size, which is not possible for the fixed sewing ring of surgical bioprosthesis (even though SAVR can be performed with root enlargement procedure). 62, 66 This aspect could partially explain the particular advantage with TAVI over SAVR in female patients. 67 Furthermore, when implanting a small (< _21 mm) surgical bioprosthesis in a young patient, it should be also considered that an eventual valve-in-valve procedure is likely to be associated with high residual gradients and an adverse prognosis. 68 
Prosthesis durability
At present, the strongest argument against broadening TAVI indication to lower-risk and younger patients remains undoubtedly valve durability. In fact, the low survival rate of current TAVI patients is attributable to the advanced age and the multiple comorbidities, not The only way to definitively determine the durability of TAVI in comparison with SAVR in the long-term would be a randomized trial in younger patients with a lengthy period of follow-up. In this regard, patients enrolled in the PARTNER 3 and Evolut R Low Risk trials are expected to be in their late seventies, and both studies have a commitment to echocardiographic 10-year follow-up, in order to provide the pivotal durability data on new-generation THVs.
Surgical bioprosthesis are known to degenerate within 10 to 20 years and this is highly age-dependant. 72 In this regard, patients younger than 60 years appear to have a long-term survival benefit when treated with mechanical valves compared with bioprosthesis.
Transcatheter heart valves deteriorate in a manner similar to surgical bioprostheses, either with stenosis (because of calcification, thrombosis, or pannus) or regurgitation (consequent to reduced leaflet mobility, endocarditis, tears, or PVL). 73 It has been hypothesized that durability of THVs may be shorter than surgical bioprostheses, because of leaflet crimping, torsion during delivery, balloon dilation, possible incomplete, non-circular THV expansion with subsequent asymmetric leaflet opening and increased sheer stress. 73, 74 However, the 5-year echocardiographic data of the PARTNER 1 trial showed that the mean THV gradient does not change throughout 5 years, with very few (<2%) haemodynamic outliers needing re-operation. 71 To date, definitions of valve degeneration is not standardized between the surgical and interventional community, and therefore a direct comparison outside randomized trials could be misleading. In most surgical reports, structural valve deterioration is defined as need for reoperation. 68 On the other hand, the VARC-2 definition of valve-related dysfunction for THV is based on echocardiography (mean aortic valve gradient > _20 mmHg, EOA < _0.9-1.1 cm 2 and/or DVI <0.35 m/s, and/or moderate or severe prosthetic valve regurgitation). 75 Notably, freedom from reoperation does not necessarily mean freedom from structural valve degeneration, and actual surgical valve degeneration might be under-reported. For example, the case of an asymptomatic patient with a mean gradient of 21 mmHg who would never undergo reoperation, would be considered valvedegeneration by transcatheter, but not by surgical definition. To note, the issue of durability is becoming increasingly important also considering the recent evidence of benefit in treating asymptomatic severe AS, 76 which will lead to anticipate the time of intervention in most patients. As we offer TAVI to patients with longer life expectancy, treatment of THV degeneration with a TAV-in-TAV approach will increase exponentially, given the high mortality associated with redo valve surgery. Recently, redo TAVI for the treatment of THV failure 77 was shown to be safe, and associated with favourable haemodynamic outcomes, particularly with lower gradients in comparison to valvein-valve procedures for the treatment of failed surgical bioprosthesis. However, several concerns about valve-in-valve therapy need to be addressed. For instance, coronary re-cannulation, which will be more .
frequent as we start treating young patients with concomitant coronary artery disease, is often challenging when two THVs have been placed. In this regard, special care should be reserved to the choice of the first implanted THV type (valve design, prosthesis height, supravs. intra-annular implantation, position of leaflet sewing, etc.), in order to minimize the potential obstruction in getting access to the coronary ostia given by the valve.
Clinical outlook
To really compete with surgery in younger, lower-risk subjects, device-, and patient-related outcomes of TAVI have to be as good as those of SAVR. To this regard, what are the performance benchmarks that TAVI has to guarantee to take on the challenge against SAVR in the low-risk patients? Reasonably, the 30-day mortality and stroke-rate should be around 1%, major vascular complications should not exceed 3%, new PM implantation-rate of less than 10% and moderate-severe PVL in less than 3% of patients would be considered acceptable. That said, in low-risk, younger patients, TAVI is unlikely to outperform SAVR in terms of hard endpoints. Nevertheless, if non-inferiority of TAVI is proven by randomized trials also in the low-risk category, patient's preference will likely go to the less invasive procedure, as previously happened for percutaneous coronary intervention and coronary artery bypass grafting. This will remain true only if careful Heart Team evaluation of clinical and anatomical characteristics (Table 6 ) is preserved.
Conclusions
An elderly patient with low surgical risk will likely benefit from TAVI, and data from European TAVI registries suggest that treatment of these patients is already part of everyday clinical practice, 78 despite the lack of robust evidence from large randomized trials. With the unanswered question of long-term THV durability, to date TAVI should not be offered to low-risk young subjects, with the clear understanding that the definitive long-term data will not be available in the near future. Any decision to perform TAVI in low-risk younger patients will require a detailed discussion with the patient of the potential limitations in regard to durability, concerns about repeated valve-in-valve procedures and the possibility of a future surgical repair. It is highly likely that the ongoing trials of TAVI in low-risk patients will demonstrate non-inferiority, but these trials and the relatively limited period of follow-up will still leave us with residual unanswered questions and a persisting clinical conundrum. 
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